Historical Stock Price
MDVN historical stock prices picture
MDVN (MDVN) has the following price history information. Looking back at MDVN historical stock prices for the last five trading days, on September 22, 2016, MDVN opened at $81.03, traded as high as $81.10 and as low as $80.94, and closed at $81.08. Trading volume was a total of 2.76M shares. On September 23, 2016, MDVN opened at $81.43, traded as high as $81.45 and as low as $81.40, and closed at $81.42. Trading volume was a total of 16.11M shares. On September 26, 2016, MDVN opened at $81.42, traded as high as $81.45 and as low as $81.42, and closed at $81.42. Trading volume was a total of 3.03M shares. On September 27, 2016, MDVN opened at $81.44, traded as high as $81.48 and as low as $81.43, and closed at $81.44. Trading volume was a total of 7.20M shares. On September 28, 2016, MDVN opened at $81.44, traded as high as $81.44 and as low as $81.44, and closed at $81.44. Trading volume was a total of 8.60K shares.

MDVN Historical Stock Prices By Date:

MDVN historical cagr picture

Below, we examine the compound annual growth rate — CAGR for short — of an investment into MDVN shares, starting with a $10,000 purchase of MDVN, and working forward through the historical stock price information to today.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 03/31/2014
End date: 09/28/2016
Start price/share: $32.19
End price/share: $81.44
Dividends collected/share: $0.00
Total return: 153.00%
Average Annual Total Return: 44.99%
Starting investment: $10,000.00
Ending investment: $25,300.21
Years: 2.50
Date Open High Low Close Volume
09/22/2016 $81.03 $81.10 $80.94 $81.08 2.76M
09/23/2016 $81.43 $81.45 $81.40 $81.42 16.11M
09/26/2016 $81.42 $81.45 $81.42 $81.42 3.03M
09/27/2016 $81.44 $81.48 $81.43 $81.44 7.20M
09/28/2016 $81.44 $81.44 $81.44 $81.44 8.60K
Medivation is a biopharmaceutical company focused on the development and commercialization of therapies to treat diseases. Co. has one commercial product, XTANDI® (enzalutamide) capsules (XTANDI), through its collaboration with Astellas Pharma, Inc. XTANDI has marketing approval in the U.S., Europe and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer, and in Japan for the treatment of patients with castration-resistant prostate cancer. Co. also has worldwide rights to talazoparib (MDV3800), an orally available poly-ADP ribose polymerase inhibitor, and pidilizumab (MDV9300), an antibody with immune-mediated anti-tumor effects.
Date Close
09/22/2016$81.08
09/23/2016$81.42
09/26/2016$81.42
09/27/2016$81.44
09/28/2016$81.44
MDVN is categorized under the Healthcare sector; below are some other companies in the same sector:

MDVX Historical Stock Prices
MDX Historical Stock Prices
MDXG Historical Stock Prices
MEIP Historical Stock Prices
MELA Historical Stock Prices
MGCD Historical Stock Prices
MGEN Historical Stock Prices
MGLN Historical Stock Prices
MGNX Historical Stock Prices
MICR Historical Stock Prices

Email EnvelopeFree MDVN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts


MDVN Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.